News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DelSite Biotechnologies, Inc. Nasal Powder Vaccine Platform Highlighted At Cambridge Healthtech Institute


8/18/2008 11:20:51 AM

IRVING, Texas, Aug. 18, 2008 (GLOBE NEWSWIRE) -- DelSite, Inc. (OTCBB:DSII) today announced Dr. Yawei Ni, Chief Scientific Officer of its wholly-owned subsidiary, DelSite Biotechnologies, Inc., presented data and development status of DelSite's GelVac(tm) nasal powder platform for vaccine delivery at the Cambridge Healthtech Institute's Third Annual Immunotherapeutics and Vaccine Summit held August 13-15, 2008, in Cambridge, Massachusetts.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES